Sargramostim for Myeloid Dendritic Cell Deficiency
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
Previous studies have demonstrated a deficiency of blood dendritic cells in patients with
kidney disease that is associated with the development of viral infections after kidney
transplantation. We plan to test the ability of sargramostim to increase blood dendritic cell
levels in patients with kidney disease in the hopes of developing new therapies to prevent
viral infections after kidney transplantation.